摘要
目的对比阿立哌唑与利培酮治疗首发精神分裂症的效果。方法将120例首发精神分裂症患者根据随机抽签法分为治疗组与对照组,每组各60例,治疗组选择利培酮进行治疗,对照组采用阿立哌唑进行治疗。结果治疗后治疗组的PANSS总分、阳性症状分、阴性症状分与一般精神病理分均明显少于对照组,差异有统计学意义(P<0.05)。治疗组的恶心、口干、便秘、体重增加等总体不良反应发生率明显低于对照组,差异有统计学意义(P<0.05)。结论相对于阿立哌唑,利培酮治疗首发精神分裂症的疗效更佳,安全性更好,值得推广应用。
Objective To compare the efficacy of aripiprazole and risperidone in the treatment of first-episode schizophrenia. Methods 120 cases of first-episode schizophrenia patients were randomly divided into the treatment group and control group,each group of 60 cases,the treatment group was treated with risperidone,tbe control group was given with aripiprazole treatment. Results After treatment,the PANSS total score,positive symptoms,negative symptoms and general psychopathology sub-points of the treatment group was significantly less than that of the control group re- spectively （P〈0.05）.The overall incidence of adverse events of nausea,dry mouth,constipation,weight gain of the treat- ment group was significantly lower than thate of the control group respectively （P〈0.05）. Conclusion Compare with aripiprazole,first-episode schizophrenia treated by the risperidone has better efficacy and safety that should be widely applied.
出处
《中国当代医药》
2014年第7期79-80,83,共3页
China Modern Medicine
